OrbiMed — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo CapitalAvoro Ventures
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)
Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017
Co-investorsAtlas VentureNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSofinnova VenturesSolasta Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.